• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Saudi Arabia·Healthcare·4002.SR
Share

Mouwasat Medical Services Company Stocks

SAR 60.85Last Updated 27.07.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Moderate

Recommendation

Hold

Market Cap

SAR 3.21B

SAR 60.85
Key Takeaways

Risk factor

Very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Mouwasat Medical Services Company, established in 1974 and headquartered in Dammam, Saudi Arabia, is a prominent healthcare provider. The company's core activities involve the acquisition, management, and operation of a wide array of medical facilities, including hospitals, clinics, pharmacies, and drugstores throughout the Kingdom of Saudi Arabia. Mouwasat operates an extensive chain of hospitals located in key cities such as Dammam, Jubail, Madinah, Khobar, Qatif, and Riyadh, delivering comprehensive medical care to its patients. Beyond general hospital services, the company features specialized centers addressing various health needs. These include dedicated skin care facilities offering cosmetic dermatology, laser treatments, reconstructive and plastic surgery, beauty services, and weight loss programs. It also provides a fertility center and a specialized clinic for bariatric surgery. Further expanding its specialized offerings, Mouwasat boasts a cardiology center for the diagnosis and treatment of heart conditions, a dedicated stroke unit, and a facility focused on managing diabetes and diabetic foot complications. The company also extends its services to include long-term care and rehabilitation. Additionally, Mouwasat Medical Services Company is active in the wholesale distribution of medical equipment and pharmaceutical products.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 4002.SR is 82.1 and suggests 36.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.07.2026 21:58

U.S. senators have agreed on “severe sanctions” against Russia. What happens next?

28.07.2026 21:28

Apple Is Preparing for a Breakthrough in the Smart Home Market — Bloomberg

28.07.2026 21:08

An Nvidia-backed fiber-optic manufacturer is heading for its worst day in 24 years. Why?

28.07.2026 21:00

SpaceX lost $1.2 trillion in market capitalization before its stock rebounded from its low

28.07.2026 19:40

"A Pure Expression of Power": How Christopher Nolan's "Odyssey" Will Change IMAX

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026